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Abstract
Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder of cilia structure, function, 
and biogenesis leading to chronic infections of the respiratory tract, fertility problems and 
disorders of organ laterality. The diagnosis can be challenging, using traditional tools such as 
characteristic clinical features, ciliary functional and ultra-structural defects; newer screening tools 
such as nasal nitric oxide levels and genetic testing add to the diagnostic algorithm. There are 
thirty-two known PCD causing genes, and in the future, comprehensive genetic testing may screen 
young infants prior to developing symptoms thus improving survival. Therapies include 
surveillance of pulmonary function and microbiology, in addition to airway clearance, antibiotics 
and ideally, early referral to bronchiectasis centers. As with CF, standardized care at specialized 
centers using a multidisciplinary approach likely improves outcomes. In conjunction with the CF 
foundation, the PCD foundation, and with lead investigators and clinicians, is developing a 
network of PCD clinical centers to coordinate the effort in North America and Europe. As the 
network grows, care and knowledge will improve.
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Background
Primary ciliary dyskinesia (PCD) is a rare, autosomal recessive disorder of motile cilia that 
leads to oto-sino-pulmonary disease.1 PCD was first described by Kartagener et al in 1936 
as a syndrome based on the triad of chronic sinusitis, bronchiectasis and situs inversus. Forty 
years later, Afzelius expanded on this by observing that these patients had “immotile” cilia 
and defective ciliary ultrastructure, specifically noting a deficiency of dynein arms, 
decreased mucociliary clearance and a lack of ciliary motion.2,3 Later on, the syndrome was 
renamed “primary ciliary dyskinesia” when it was observed that functional ciliary 
impairment without ultrastructural deformities, as well as motile cilia with obvious 
abnormal movement patterns could result in clinical disease.4–6 The prevalence of PCD is 
difficult to determine due to (hitherto) inadequate diagnostic methods and often an under-
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recognition of the syndrome; it is estimated to be ~1 in 15,000–20,000 individuals.7 Focused 
clinical and research efforts in recent years have led to an increased understanding of the 
phenotype, as well as the discovery of PCD-causing genetic mutations. Indeed, the use of 
genetic testing has greatly aided the diagnosis of PCD and further helped the understanding 
of PCD. Nonetheless, even with improvements in diagnostic and screening tests at 
specialized centers, up to 30% of patients may be missed. Secondary ciliary dyskinesia may 
be seen in diseases associated with acute and chronic airway inflammation and infection.
This review will focus primarily on PCD, the genetically transmitted form of the disease, 
with a brief review of the structure and function of normal and dysfunctional cilia, the 
clinical manifestations of PCD, including diagnosis, genetic mutations, therapies and a 
glimpse into future.
Normal cilia structure and function
Respiratory cilia are an important part of airway host defense, protecting the airways from 
inhaled pathogens, allergens and other inhaled noxious particles via the mucociliary 
escalator. In the airways, they are surrounded by a thin, watery, peri-ciliary fluid layer 
overlaid by a more viscous mucus layer. The efficiency of the mucociliary escalator in 
defense of the airway depends on the viscosity and composition of the peri-ciliary fluid and 
mucus layer, the integrity of the airway epithelium and the synchrony and beat frequency of 
the cilia. The density of cilia decreases from the upper to the lower respiratory tract with an 
absence of cilia in the alveoli and air sacs.8 Cilia are hair-like attachments found on the 
epithelial cell surfaces (~200 per cell) of various organs. The cilia basal body attaches to the 
apical cytoplasm on the cell surface and extends into the extracellular space. They are 
composed of α- and β-tubulin monomers organized into longitudinal microtubules. The 
axonemal structure consists of a circular arrangement of nine microtubule doublets 
surrounding a central pair of microtubules (9+2) or with an arrangement where the central 
pair is absent (9+0).9 Cilia are categorized into 9+2 motile cilia with dynein arms, 9+0 
motile cilia (nodal cilia) with dynein arms and 9+0 non-motile cilia lacking dynein arms.10
“9+2” motile cilia are found on the apical surfaces of the upper and lower respiratory tract, 
on the ependymal cells lining the ventricles of the central nervous system, in the oviducts 
and in the flagellum of sperm.10 Outer dynein arms (ODAs) and inner dynein arms (IDAs) 
traverse along the length of the peripheral microtubules forming a doublet (Figure 1) and are 
organized into nine microtubule pair doublets, surrounding a central pair. This organizational 
structure creates this distinctive 9+2 arrangement. The central pair is linked to the 
surrounding pair doublet through radial spoke proteins and the surrounding pair doublets are 
linked to one another via nexin linked proteins (Figure 1). The microtubules slide by one 
another to produce ciliary motion via an ATP-containing dynein arm on the peripheral 
microtubule. The protein links between the microtubules limit the degree of sliding, causing 
them to bend. Through coordinated and synchronized bending, wave like movements occur 
at ~6–12 Hz, which function to propel mucus and adherent particles/bacteria on the surface 
of the airway – hence the term “mucociliary escalator”. The ability of numerous adjacent 
cilia on airway epithelial cells to beat at such a high frequency in part reflects the very low 
friction among the cilia, which results from negatively charged glycoproteins that coat the 
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ciliary shaft. Thus, given such an efficient, if complex, system of defense, it can readily be 
visualized that clinical disease may result from disruptions in the various components of the 
system. For example, Cystic Fibrosis results from abnormalities in the Cystic Fibrosis 
Transmembrane Regulator (CFTR), a critical airway surface epithelial protein. Similarly, 
mutations in genes encoding for axonemal structures of the functional components of motile 
cilia, or proteins involved in the biogenesis of cilia, including cytoplasmic proteins, can 
result in clinical disease; PCD.11–14
Although dysfunctional motile cilia lead to the main clinical manifestations of PCD, 
abnormal nodal motile cilia can also lead to interesting phenotypic features. Nodal cilia 
occur during embryonic development and have a 9+0 configuration rather than the classic 
9+2 configuration and are found on the epithelial cell surface of the kidneys, the bile ducts, 
and the endocrine pancreas and on non-epithelial cells such as chondrocytes, fibroblasts, 
smooth muscle cells and neurons. In contrast to the waveform sliding motion of 9+2 cilia, 
nodal motile 9+0 cilia beat with a vertical /rotational motion resulting in a leftward flow of 
extracellular fluid which is important for cell signaling during the development of normal 
human left-right asymmetry. Mutations in the genes that encode the outer doublets result in 
laterality defects (situs inversus for example) while mutations in the genes that encode the 
non-directional central apparatus (central complex, radial spoke), do not.15 This represents a 
predictable genotype – phenotype relationship (see below).
Phenotypic features
Overview
Cells lining the nasopharanx, middle ear, paranasal sinuses, the lower respiratory tract and 
the reproductive tract contain cilia; these cilia are abnormal in structure and function in 
PCD, leading to clinical expression of disease. The clinical manifestations of PCD are thus 
predictable, with an age-dependent, and organ system spectrum of presentation (Table 1). 
Symptoms of PCD can occur at birth, or within the first several months of life. Normal 
ciliary function is critical in the clearance of amniotic fluid from the fetal lung; over 80% of 
full term neonates with PCD have a syndrome of respiratory distress. Unexplained 
respiratory distress, radiographic abnormalities, atelectasis in particular, and hypoxia in a 
full term infant should raise the suspicion for PCD.16,17 Almost all children with PCD have 
a daily productive cough, a logical symptom, since cough can partially compensate for the 
dysfunctional mucociliary clearance. However, recurrent bacterial infections of the lower 
airways ultimately leads to bronchiectasis, which is seen in virtually all adults older with 
PCD.16–18 Despite aggressive medical care, PCD is generally a progressive disease and 
some patients develop severe disease, respiratory failure, and/or require lung 
transplantation.1
Airway microbiology
Regular surveillance of the respiratory flora is important, as a variety of organisms may 
colonize or infect the lung, which may require targeted therapy because of resistance, or lead 
to specific infectious problems (e.g. non-tuberculous mycobacteria; NTM). Monitoring 
protocols developed for cystic fibrosis and PCD patients vary but most centers obtain airway 
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cultures every 3 to 6 months. The respiratory microbiology in PCD generally mirrors that of 
CF, however, in PCD colonization with Pseudomonas aeruginosa generally occurs later, and 
the incidence of S pneumonia is much higher.1 Children with PCD have airway colonization 
with Haemophilus influenza, Staphylococcus aureus and Streptococcus pneumoniae and, 
recently, there has been an upsurge of P. aeruginosa in infants/preschoolers. P. aeruginosa 
(smooth and mucoid varieties) normally occurs in teenagers and young adults and is often 
the dominant organism in adults with PCD. NTM are seen in ~15% of adults with PCD.1
Lung Function
Patients with PCD, as with other patients with non-CF bronchiectasis, usually develop 
progressive airway obstruction as the disease advances. The disease progression is usually 
slower than seen in CF, however, it is just as important to follow lung function serially to 
establish a baseline, to help guide therapy, and to determine prognosis.18–20
Radiology
High resolution chest computed tomography scan (HRCT scan) is the most sensitive 
imaging modality to diagnosis bronchiectasis. While HRCT cannot confidently distinguish 
between the different etiologies for bronchiectasis (PCD, vs idiopathic, vs post infectious 
etc), there are disease distributions that may support specific diseases. For example, PCD 
may be associated with more bronchiectasis in the middle and lower lobes, as compared 
with CF which usually shows more disease in upper lobes.21 Subtle lung disease may start 
early in life, as HRCT scans of infants and children with PCD show sub-segmental 
atelectasis, peri-bronchial thickening, mucus plugging, evidence of air trapping and ground 
glass opacities. HRCT may show bronchiectasis even in infancy, and its frequency increases 
with age. The absence of bronchiectasis on a HRCT scan of an adult virtually excludes PCD 
from the differential.21,22
Non-pulmonary manifestations
Situs abnormalities results in early diagnosis thus it is found in ~60% of newly diagnosed 
pediatric patients and ~50% of newly diagnosed adults. The defect is in the 9+0 nodal motile 
cilium during embryogenesis whose unidirectional rotational beat determines normal 
thoraco-abdominal orientation. Without this, thoraco-abdominal orientation develops at 
random, resulting in a 50% incidence in adults.15 More recently this phenotypic expression 
of situs abnormalities has expanded to include other clinical manifestations, including that of 
cardiac abnormalities; ~6% of patients with PCD have congenital heart disease.23 
Spermatozoa depend on cilia for motility thus infertility is seen in almost all males with 
PCD. However, a small number of men with PCD have appeared to conceive naturally. 
Females have abnormal cilia in their fallopian tubes with longer ovum transit time, and there 
appears to be an increased incidence of infertility and ectopic pregnancies.24 Less clear 
phenotypic associations include pectus excavatum (10%), scoliosis (5–10%), retinitis 
pigmentosa and hydrocephalus.25
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A precise diagnosis of PCD may be difficult, especially in non-classic clinical situations (for 
example, without situs abnormalities). Often, only specialized centers have the resources to 
make a definitive diagnosis (see below). Obviously the presence of any laterality 
abnormalities, or congenital heart disease, in the presence of chronic respiratory disease 
should prompt the notion of PCD as a potential unifying cause. A history of unexplained 
neonatal respiratory distress, early onset and persistent nasal-pulmonary symptoms, 
unexplained bronchiectasis, a family history of PCD and immotile sperm/infertility should 
trigger an evaluation. There is overlap with other chronic respiratory diseases particularly 
CF, although immunologic deficiencies, allergic broncho-pulmonary aspergillosis (ABPA), 
and recurrent aspiration may also be in the differential. Early referral to a specialized center 
is recommended for both diagnosis and management, given the complex nature of the 
disease, and the rapid nature with which new information is emerging in relation to 
diagnosis and management.
Indirect assessment of ciliary function
Saccharin Test—The saccharin test was a traditional simple, indirect way to test ciliary 
function, and was used as a screening tool for PCD at many centers. A 1–2mm particle of 
saccharin is placed on the inferior nasal turbinate and the time it takes the patient to taste the 
saccharin is a rough estimate of nasal mucociliary clearance. However, at best it is crude, 
limited by technical errors (inadequate placement of saccharin), patient compliance (unable 
to sit still for test, especially children) and false positives (poor sense of taste, rhino-
sinusitis). Thus, it is rarely used currently, and has been superseded by the more accurate 
tests below.
Nasal Nitric Oxide (NO) levels—The fortuitous observation several years ago that levels 
of NO produced in the upper airway are reduced in PCD led to the concept that nasal NO 
levels could be used as screening test in PCD.26 NO is produced by the para-nasal sinus 
epithelium via NO-synthase and low levels are seen in PCD, CF, acute/chronic sinusitis and 
nasal polyposis. In patients with PCD however, levels of exhaled NO are extremely low 
(~10% of normal value) when compared to these other diseases. Interestingly, carriers of 
PCD have been shown to have intermediate levels of exhaled NO.1,27,28 Using a 
standardized protocol, nasal NO measurements can accurately identify patients with PCD 
98.6% of the time.29
Direct assessment of ciliary function
Microscopic analysis—Function can be classed as qualitatively normal, dyskinetic or 
immotile with direct visualization of ciliary beat pattern and frequency with microscopic 
analysis of trans-nasal brushings or nasal scrapes of the inferior turbinate. However, this test 
is technically difficult outside of research centers, and is neither sensitive nor specific.30
High-speed digital video imaging—Trans-nasal brushing or nasal scrape ciliated 
epithelial samples can be analyzed with high-speed digital video imaging to get quantitative 
measurements of the ciliary beat frequency (CBF) to help differentiate between abnormally 
beating cilia and normal beat patterns.9,31 The cilium can be viewed in slow motion, with 
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40–50 frames per ciliary beat cycle. Normal cilia beat back and forth within the same frame 
with no sideways recovery sweep. CBF and beat pattern abnormalities are associated with 
specific ultra-structural defects including transposition and defects in isolated outer arms, 
isolated inner arms and radial arms.32 Active sinusitis can cause secondary ciliary 
dysfunction resulting in false positives, and thus samples should be obtained when the 
patient is relatively stable clinically. A normal CBF and beat pattern is sensitive enough to 
exclude classic PCD, but any abnormality should provoke further testing.27 Thus, this test 
(like other studies of cilia, often available at only research centers) should be used along 
with structural, and genetic analysis to confirm the diagnosis.
Assessment of ciliary ultrastructure
Transmission electron microscopy33—Once the suspicion for PCD is high, the 
axonemal structure of the respiratory cilia may be studied using transmission electron 
microscopy, the traditional way of diagnosing PCD since Afzelius’ first report in the 
mid-1970s.2 Various ciliary ultrastructural defects have been described, including the 
absence of, or alteration in, inner dynein arms (IDAs) or outer dynein arms (ODAs), absence 
of the central pair, or defect of radial spokes.34 The most common ultra-structural defect in 
PCD is either the absence or shortening of an ODA (55% prevalence) or a combined 
absence/shortening of both the IDA and the ODA (15% prevalence). Other abnormalities 
include defects in the IDA alone or in combination with defects in radial spokes, central 
microtubule pairs (transposition) or central microtubular agenesis. Thus, until recently, the 
identification of ultrastructural defects on TEM was the “gold standard” for the diagnosis, 
however, with advances in our molecular understanding in PCD, it is known that ~30% of 
patients with genetically proven PCD have normal ciliary ultrastructure and in some cases, a 
ciliary a- or oligoplasia, hence inadequate for the TEM analysis. In addition, the technique is 
limited by false positive conditions (those associated with active mucosal epithelium 
inflammation, viral or bacterial), inadequate samples, poorly processed samples and reader 
error.35–38 Studies have shown a 3–10% prevalence of defective cilia in the airways of 
healthy individuals, and normal ultrastructure in up to 15% of PCD patients.39 Dependence 
on TEM alone therefore is an unreliable way of solely diagnosing PCD.
Flourescence-labeled antibodies—Immunoflourescent analysis using antibodies 
directed against the main axonemal components has been used to identify structural 
abnormalities of cilia. For example, PCD patients with ODA defects have absence of 
DNAH5 staining from the entire axoneme and accumulation of DNAH5 at the microtubule 
organizing center. Antibody based techniques can diagnose defects in both the ODAs and 
the IDAs caused by the KTU mutation in PCD. Currently, a panel of antibodies directed 
towards multiple ciliary proteins is being developed that may add to the diagnostic 
armamentarium in screening for PCD, however, like many sophisticated techniques, it is 
restricted to a few centers that have this technology.40
Genetic testing
PCD is a recessive disorder, and exhibits locus and allelic heterogeneity. That is, multiple 
genes are involved in the disease, and different mutations in the same gene may also cause 
PCD. Mutations in eleven different PCD- causing genes have been described between 1999 
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and 2010 with linkage mapping and/or candidate gene testing. An additional 23 genes have 
been discovered since 2011 owing to the availability of whole exome sequencing (Table 2). 
Some of these genes (for example DNAH8 and NME8) have only been seen in few patients, 
thus replication studies are necessary. About 80% of the mutations are loss-of-function 
variants (nonsense, frame shift, or defective splice mutations) while the others are 
conservative missense mutations or in-frame deletions. Most mutations occur in only one 
patient/family (“private” mutations) a few of the mutations have been seen to recur in two or 
more unrelated patients. Collaborative efforts in recent years have allowed the collection of 
large amounts of data from across many clinical centers in the US and Canada and thus 
facilitated large scale genetic studies and identification of many causative genes, which had 
previously been very difficult to do in this rare disease.41 Approximately 65% of the 200 
PCD patients in the rare disease consortium (Genetic Disorders of Mucociliary clearance; 
GDMCC) have biallelic mutations (mutations in both copies of the same gene). At this 
point, with the use of next generation sequencing, ~66% of patients with PCD can be 
identified therefore facilitating early diagnosis and treatment.40,42–45 This is especially 
helpful in the cases where ciliary ultrastructural analysis is equivocal or inadequate.
As the basic structure of the cilia is highly conserved across species, non-human models 
have helped in the discovery of PCD genes and the effects of the mutations on the cilia. 
Multiple publications have documented the effects of specific mutations on the cilia 
structure and function. Some of the genes code for proteins in the ODA, IDA or radial spoke 
causing specific dysfunction or dysmotility while others are expressed by proteins in the 
cytoplasm used for the pre-assembly of the cilia causing loss of both the ODA and the IDA 
leading to cilia immotility.43,46–48 Recently, two proteins (CCNO and MCIDAS) have been 
shown to affect cilia biogenesis.49,50 Specific classes of mutations are associated with 
specific phenotypes. Mutations in genes that lead to loss of function of the cilia also lead to 
low nasal nitric oxide (NO) levels (<77nl/min). Mutations that affect the dynein arm’s 
ultrastructure lead to situs abnormalities while mutations that affect the central apparatus do 
not. Mutations in patients with normal TEM can have cilia with normal beat frequencies and 
waveforms.
Overall, the more that is learnt about the molecular basis of PCD, the more is learnt about 
the spectrum of phenotypes, ranging from “classic” to mild, that associated with late 
presentation, or that with normal cilia structure, analogous to the experience with CF – 
classic, early presentation disease versus non-classic disease often presenting later in life, or 
even well into adulthood.
Therapies
As there are currently no therapies available that can reverse the underlying ciliary 
abnormalities, the goals of therapy are to prevent exacerbations and slow the progression of 
the disease. As with other forms of CF and non-CF bronchiectasis, patient education is a 
critical part of the care plan, including imparting an understanding of the underlying cause 
of the disease, its prognosis and the various therapies available to try to control the 
symptoms, especially airway clearance. Currently, there are no data from randomized 
clinical trials to support any particular forms of therapy, thus, most management strategies 
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(including those discussed below) are extrapolated from CF and non-CF bronchiectasis. As 
with any chronic disease, usual good health practices such as refraining from smoking, and 
administration of recommended immunizations including influenza, and pneumococcal 
vaccines.
Surveillance
To guide the management plan, regular (twice yearly to quarterly) lung function testing is 
recommended, together with microbiologic assessments of airway flora (using either 
expectorated sputum, or induced samples using 3–7% hypertonic saline) is recommended to 
establish clinical trends and detect exacerbations, thus allowing targeted anti-microbial 
therapy. A baseline computed tomogram (CT) scan is useful to assess the nature and extent 
of disease (as noted above bronchiectasis may be evident even in young patients), followed 
by periodic chest imaging to track disease progress, or, to assess the significance of new 




There are no data to support any particular form of airway clearance in PCD, but clinical 
experience supports its use in a form acceptable to the patient. Daily airway clearance with 
cardiovascular exercise, use of percussion vests, manual chest physical therapy and valve/
positive pressure expiratory devices help mobilize and aid expectoration of broncho-
pulmonary secretions, improve efficiency of ventilation, maintain/improve exercise tolerance 
and reduce breathlessness.
Osmotic agents
“Hydration” therapy of the airway is an attractive concept to augment clearance of secretions 
in a disease such as PCD, in this case “cough clearance” given the dysfunctional cilia.51 
Nebulized hypertonic saline (3%–7% hypertonic saline) modulates the liquid content of the 
peri-ciliary fluid layer via increased hydration, thinning thick secretions and triggering 
cough in the CF population. It has been shown to improve lung function, quality of life, and 
reduce antibiotic needs in the non-CF bronchiectasis population.51,52 More recently, another 
agent which works via the osmotic approach is inhaled mannitol, again studied in non CF 
bronchiectasis rather than specifically PCD.53 Although the inhaled drug (400 mg BID) did 
not achieve its primary outcome of reducing exacerbations, it did perform better than 
placebo (low dose mannitol) in slowing down the time to first exacerbation and improving 
the quality of life measures.
Deoxyribonuclease (Dornase α)
Dornase α is an enzyme that hydrolyses eukaryotic DNA released from decaying neutrophils 
to reduce mucus viscosity and aid airway clearance in the CF population.54 It is however, 
not beneficial in the non-CF bronchiectasis population, as studies show that the drug is 
associated with pulmonary exacerbations and a decline in lung function.55
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Given the propensity for chronic infection, as with other forms of bronchiectasis, antibiotics 
are the cornerstone of treatment for PCD exacerbations (usually associated with an increase 
in cough, dyspnea, wheeze, with a change in sputum volume or character, or purulence, or 
hemoptysis) as they generally improve symptoms and hasten recovery.56,57 Antibiotic 
therapy should be based on prior respiratory culture data, and previous therapeutic 
responses. Susceptibility patterns and clinical responses may guide physicians between oral, 
inhaled and intravenous routes of administration. There are no randomized data to support 
any particular drug, or route of administration, and clinical judgment is required; however, 
milder exacerbations often respond to oral or oral/inhaled combinations, while more 
significant exacerbations usually require systemic antibiotics (in combination, if gram 
negative organisms are cultured). There is a good deal of interest in the development of 
inhaled antibiotics in recent years in non-CF bronchiectasis, and over the next five to ten 
years it is likely there will be more approved drugs with better evidence of efficacy available 
(a reduction in exacerbation frequency, bacterial burden) for example inhaled 
aminoglycosides, and quinolones.58–60 Early attempts to eradicate newly acquired bacteria, 
especially P. aeruginosa, are recommended however, this has not been shown to preserve 
lung function. Chronic or cycling oral or inhaled antibiotics may be used in patients with 
frequent exacerbation to try to improve quality of life, reduce exacerbations and (hopefully) 
stabilize lung function.56,58,61,62
Anti-inflammatories
A variety of anti-inflammatory agents including oral prednisone, inhaled corticosteroids and 
macrolides have been used in airways disease associated with bronchiectasis. Prednisone is 
generally not efficacious in the CF population outside of co-existent asthma, and ABPA and 
there are no studies in the PCD population. Inhaled corticosteroids have not been shown to 
be beneficial in non-CF bronchiectasis.
The bets data for “preventive” therapy comes from recent studies using oral macrolides 
which have shown promising outcomes in non-CF bronchiectasis, with reductions in 
exacerbation frequency, delayed time to first exacerbation and reduced hospitalizations. It is 
unclear if this benefit is from an anti-inflammatory or antimicrobial effect. Prior to initiating 
therapy with a macrolide, patients should be tested for NTM, in case macrolides should form 
part of a multi-drug regimen, and to avoid the emergence of resistance from chronic single 
agent macrolide use.63–65
Miscellaneous approaches
Lung resection—Surgery may be considered in areas of localized lung disease if it is 
causing severe systemic symptoms, frequent exacerbations or recurrent/life threatening 
hemoptysis despite aggressive medical therapy. Patients in such situations have undergone 
successful resection but long-term data are lacking.66 Often the diffuse nature of disease 
elsewhere in the lung mitigates against the likelihood of success in resecting more diseased 
parts of the lung.
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Lung transplant—PCD patients undergoing double lung transplantation generally have 
good survival outcomes (personal communication?). The usual concerns pertain to 
candidacy for the procedure, but also specifically include multiply drug resistant organisms, 
and poor nutritional status. Interestingly, patients with situs inversus, do not pose any 
additional risk to post-transplant outcomes; the anatomic disorientation is challenging but 
not a contraindication.67
Extra pulmonary disease management
Otitis media—Management may be controversial, especially in the pediatric community. 
The long-term sequelae of chronic disease in the upper airway include conductive hearing 
loss, delayed speech and language development, and cholesteatoma formation. Standard 
medical therapy is recommended for acute episodes. There are not enough data on surgical 
tympanostomy to make a definitive statement regarding its utility; experts argue against the 
utility of this approach.27 Regular audiology assessments are encouraged.68,69
Chronic Sinusitis—As with CF, the sinuses are usually involved. Management includes 
nasal steroids, nasal lavage and intermittent antibiotic lavages and systemic antibiotics. 
Otolaryngology evaluation for surgery and polypectomy to promote sinus drainage is helpful 
for patients refractory to medical therapy.70
Infertility—Male infertility is secondary to sperm immotility and assisted fertilization 
techniques such as intra-cytoplasmic sperm injections are promising. Female infertility is 
secondary to sluggish fallopian tube transit time and direct ovum harvesting with in vitro 
fertilization leads to successful pregnancy.
Prognosis
As compared with CF, the disease severity and deterioration in lung function is less marked, 
especially with appropriate medical therapy. A study by Ellerman and Bisgaard reported that 
adults had worse lung function at time of diagnosis as compared to adolescents, however, 
once diagnosed and therapy started, no further lung deterioration was noted.71 However, 
other studies have shown progression to severe lung disease prior to adult hood. These 
discrepancies in severity and survival may relate at least in part to the genetic and 
phenotypic heterogeneity of PCD, as well as the usual aspects of access to care, socio-
economic backgrounds, of patients, and accompanying co-morbidities. Overall, the majority 
of patients with PCD appear to have a near normal life expectancy when compliant with 
recommended therapies. A minority of patients develop progressive severe bronchiectasis, 
end stage lung disease and early death, unless they undergo lung transplantation.71
Summary and into the future
In the past two decades, much has been learned about PCD. Accurate and earlier diagnosis is 
possible, and access to specialized centers has become easier. Standardized care at 
specialized centers using a multidisciplinary approach is expected to improve outcomes. The 
recent creation of the PCD foundation has facilitated the creation of a network of PCD 
clinical centers to help achieve this goal. As the network grows, and clinicians and research 
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scientists accumulate more data from growing numbers of PCD patients, care and 
knowledge will undoubtedly improve. In parallel, genetics correlates with larger clinical 
datasets have shown that PCD is a genetically heterogenous disease with different mutations 
in several genes resulting in a phenotype spectrum, across many races and ethnic groups. 
The severity of disease ranges from mild to severe. Delays in recognition may result in the 
development and progression of irreversible lung disease. In CF, early identification and 
diagnosis leads to early treatment and frequent monitoring to decrease morbidity and 
mortality, and one assumes the same principles apply to PCD, despite differences in 
pathogenesis. Still, it must be remembered that PCD is not the same as CF, and management 
is not identical. Without large numbers of patients with PCD, there has hitherto been little 
incentive for industry to pursue drug development, thus currently we rely on studies in non-
CF bronchiectasis (muco-active agents, macrolides, inhaled antibiotics). However, as noted 
above, with the creation of clinical and research networks, with improved identification and 
more accurate diagnosis of PCD, we can expect larger cohorts of PCD patients available to 
participate in longitudinal studies of the natural history of the disease, as well as studies of 
novel therapies, with the goal of improving clinical care and outcomes in this rare disease.
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Diagrammatic representation of a normal ciliary cross section illustrating major ultra-
structural components.
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Figure 2. A diagnostic algorithm for Primary ciliary dyskinesia (PCD)
*But if clinical suspicion is still high for PCD, may go to other, more specific tests
**A nasal NO level less than 77 nl/minute has a sensitivity and specificity of 0.98 and >0.99 
respectively
***Normal ciliary beat frequency and pattern does not exclude PCD
Nml: normal; PCD: Abnml: abnormal, NO: nitric oxide
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Table 1
Clinical Signs and Symptoms of Primary ciliary dyskinesia
By system affected By age of presentation
• Middle Ear
➢ Chronic otitis media with tube placement
➢ Conductive hearing loss











➢ Male/female fertility problem or history of in 
vitro fertilization
• Laterality defects
➢ Situs inversus totalis
➢ Heterotaxy (+/− congenital cardiovascular 
abnormalities)





➢ Communities or ethnicities with consanguinity
➢ Close (usually first degree) relatives with clinical 
symptoms
• Antenatal
➢ Heterotaxy on prenatal ultrasound
• Newborn period
➢ Continuous rhinorrhoea
➢ Respiratory distress or neonatal pneumonia
• Childhood
➢ Chronic productive cough
➢ Atypical asthma unresponsive to therapy
➢ Idiopathic bronchiectasis
➢ Chronic rhinosinusitis
➢ Recurrent otitis media with effusion
• Adolescence and adult life
➢ Same as for childhood
➢ Subfertility and ectopic pregnancies in females
➢ Infertility in males with immotile sperm
➢ Sputum colonization with non-tuberculosis 
mycobacterium or smooth/mucoid pseudomonas
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